Research Article
Biological Safety Studies and Simultaneous Determination of Linagliptin and Synthetic Impurities by LC-PDA
Table 1
Parameters of system suitability of the analytical method developed and results recommended by the FDA [25].
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
LGT: linagliptin; IMP 1: impurity 1; IMP 2: impurity 2; IMP 3: impurity 3. |